A new treatment option for Dravet syndrome

Conclusions about the cardiovascular safety of fenfluramine were limited by the short treatment and observation period of 14 weeks.
Conclusions about the cardiovascular safety of fenfluramine were limited by the short treatment and observation period of 14 weeks.